What's Hot
View all perspectives
Dr. Rachel Tate
1 year ago
Review of the limitations and possible toxicities with CAR-T treatment. ICANs and CRS, while treatable, are very important to educate and understand. This is part of the intersection of heme/onc and rheum. https://t.co/itbwLdHuqf
Dr. John Cush RheumNow
1 year ago
RheumNow’s expanded coverage of the #ACR23 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Richard Conway
1 year ago
Rector et al. Pregnancy outcomes in vasculitis. More spontaneous abortion, elective termination, ectopic & molar pregnancy, x2 preterm delivery. Preeclampsia in 12%. Worse again in small vessel vasculitis Abstr#2425 #ACR23 @RheumNow https://t.co/cotncE16ma https://t.co/QoJpJIHJfJ
Dr. Antoni Chan
1 year ago
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/2ExboBvo2W https://t.co/FuqXdFFwqP
Janet Pope
1 year ago
What % of pts in #RCTs in #SLE go in to #LLDAS - Pooling 5 RCTs - starting on #belimumab vs #placebo? More w #bDMARD @RheumNow @ACRheum #ACR23 abst#2551. True w DORIS - #lupus #rem but overall lower rates in each group https://t.co/VPZrYCVjof
Aurelie Najm
1 year ago
The perks of a conference in San Diego
The midday break with a view 🌞 🛥️
@RheumNow #ACR23 https://t.co/IRh7IRpWJz
Eric Dein
1 year ago
A#2545 IV SEC for SpA #ACR23 @Rheumow
Approved by FDA, though diff dose
Who: Medicare/cost/QoL benefit for IV or obese (wt based dose)
W16: 41% ASAS40 v 23% PBO
W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%)
SAE 6%, discontinuation 3.5%
#ACRBest https://t.co/ruW0ys49gk
Bella Mehta bella_mehta
1 year ago
Development of New classification crieteria to target patients earlier in thier #OA disease course!
One tatget molecule will not solve this heterogeneous disease! @rheumnow #ACR23 https://t.co/waynA6RdUg
KenWarringtonMD MdWarrington
1 year ago
Intriguing data on #GCA treated with tocilizumab
#aneurysm still occurs
#vasculitis https://t.co/6cPlFRReLJ
Eric Dein
1 year ago
A#2546 Anti-IFX Ab in AS
#ACR23 @RheumNow
Anti-IFX in 45% in f/u, 85% in 1st yr
MTX decr anti-IFX (18 v 42%)
Anti-IFX - higher inflamm markers, infus rxn, lower serum levels and Rx fail
Pt w/o anti-IFX Ab more likely to tolerate tapering https://t.co/eN9SqGyGgm
Richard Conway
1 year ago
Nepal et al. No increased risk of GI perforation for tocilizumab in GCA HR 1.05 . Diverticulitis (RR 3.51), IV methylprednisolone (RR 5.41) risk factors. This fits with my priors, steroids are a bigger risk than tocilizumab. Abstr#2560 #ACR23 @RheumNow https://t.co/BAmBQA0kEP https://t.co/zRjmDIkOHp
Janet Pope
1 year ago
After attaining #remission or #LLDAS after a flare - HALF flare over f/u esp if tapering pred to <7.5 or 5 mg. #HCQ was protective. 65% got LLDAs and 45% rem in 1/2 yr - longer time to get #remission #2553 #ACR23 @RheumNow @ACRheum #ACRbest Asian cohort of #SLE largest@in world https://t.co/yBBqYJZVOe
Mike Putman EBRheum
1 year ago
Great work @HoromanskiMd on a vasculitis in pregnancy plenary session! #ACR23 https://t.co/WSmqJjfBes
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
TM65 @ #ACR23
65 yo white M p/w 9mo of cryptogenic strokes.
PMH: HTN, Crohn's
- 07/2022: CRAO, BMRI: L frontal lobe infarct --> ASA, Atorvastatin started
- 09/2022: weakness, vision changes
--> BMRI: multifocal subacute infarcts --> Apixaban started, Vedolizumab started for… https://t.co/pjoCv7PH9Y https://t.co/YUN78nn6Xb
Poster Hall